pSivida plunges on FDA knock-back
Stocks in Perth-based biotech pSivida have halved in value after the United States Food and Drug Administration declined to approve its treatment for back-of-the-eye problems associated with diabetes.
At close of trade this day pSivida’s stock had lost 48.7 per cent, to trade at $2.10.
The FDA stated there was not sufficient data to prove that pSivida’s ILUVIEN treatment of diabetic macular edema associated with diabetic retinopathy was safe and effective.
According to the FDA, adverse reactions to the treatment were significant, and were not offset by the benefits of the drug.
“We are obviously surprised and disappointed with the FDA’s decision,” pSivida chief executive Paul Ashton said.
A decision on whether the treatment will be made available in Europe is expected in the first half of next year.
source : www.wabusinessnews.com.au
Related News:
- First gene therapy successful against aging-associated decline: Mouse lifespan extended up to 24% with a single treatment
- Scientists uncover potential treatment for painful side effect of diabetes
- Cancer treatment delivery: International Space Station’s microgravity platform
- Ryan O’Neal To Undergo Pioneering Cancer Treatment
- Study points to potential treatment for stroke
- Antipsychotic drug may be helpful treatment for anorexia nervosa
- Treatment of ischemic heart failure with bone marrow cells does not show improvement for certain heart function measures
- Heroin treatment more cost-effective than methadone
- Antidepressant shows promise as cancer treatment
- Brain-derived neurotrophic factor: Finding may have implications for Rett Syndrome, other neurological disorders
Details :
Submited at Monday, November 14th, 2011 at 10:00 pm on Business by Alina
Comment RSS 2.0 - leave a comment - trackback